TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33569757

Group type: EXPERIMENTAL
Intervention: One implant in the midline of the mandibular symphysis (GA group)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Two implants in the lower canine region (GB group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Two implants (GB group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: One implant (GA group)
Number of subjects: 18
Study: 33475536

Group type: EXPERIMENTAL
Intervention: Neuromobilization (NM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 80
Study: 33810773

Group type: EXPERIMENTAL
Intervention: Online motivational interviewing training program (Group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Online motivational interviewing training program and live booster session (Group 2)
Number of subjects: 44
Study: 32013830

Group type: EXPERIMENTAL
Intervention: FCSM (fermented cottonseed meal)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ct‐Sc CSM (fermented cottonseed meal with C. tropicalis plus S. Cerevisae)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Unfermented CSM (control group)
Number of subjects: 180
Study: 35314068

Group type: EXPERIMENTAL
Intervention: coDiagnostiX
Number of subjects: 24

Group type: COMPARATOR
Intervention: Implant Studio
Number of subjects: 24
Study: 32169149

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam combined with tigecycline
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam sodium alone
Number of subjects: 114
Study: 33789549

Group type: EXPERIMENTAL
Intervention: Health intervention
Number of subjects: 1056
Study: 32880954

Group type: EXPERIMENTAL
Intervention: SDoH V-codes
Number of subjects: 5313965

Group type: COMPARATOR
Intervention: Medical diagnoses without SDoH V-codes
Number of subjects: 5313965

Group type: COMPARATOR
Intervention: Combined SDoH and medical diagnoses codes
Number of subjects: 5313965

Group type: EXPERIMENTAL
Intervention: Index of 40 SDoH codes
Number of subjects: 5313965
Study: 2011315466

Group type: EXPERIMENTAL
Intervention: Essential fatty acid (EFA), fibrin sealant, and Unna's boot (Group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Essential fatty acid (EFA) and Unna's boot (Group 1)
Number of subjects: 24
Study: 35643253

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) plus standard of care (SOC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Palliative standard of care (SOC)
Number of subjects: 99
Study: 34037821

Group type: EXPERIMENTAL
Intervention: Shake containing 30g of cashew nuts and 15g of Brazil nuts
Number of subjects: 15

Group type: COMPARATOR
Intervention: Shake absent of nuts (matched for energy and macronutrient content)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Shake containing nuts
Number of subjects: 15

Group type: COMPARATOR
Intervention: Shake absent of nuts
Number of subjects: 15
Study: 33318380

Group type: EXPERIMENTAL
Intervention: Opioid users (cases)
Number of subjects: 436
Study: 33753954

Group type: EXPERIMENTAL
Intervention: Group counseling with a client-centered approach based on the GATHER principles
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine counseling (Control)
Number of subjects: 72
Study: 32578353

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 134
Study: 34214989

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training, 30-Hz frequency, 3 series of four 45-s exercises with a 45-s rest, total of 12 sessions (2 sessions per week for 6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 16
Study: 33057953

Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: ENTOCORT EC 9 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BOS 2 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BOS 2 mg and ENTOCORT EC 9 mg
Number of subjects: 22
Study: 36182772

Group type: EXPERIMENTAL
Intervention: active-tDCS
Number of subjects: 50
Study: 33610485

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (InGaAs diode laser, 980nm, 100mW, 10J per tooth)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no photobiomodulation)
Number of subjects: 22
Study: 32917160

Group type: EXPERIMENTAL
Intervention: 5 Star Toilet campaign intervention
Number of subjects: 2483

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2483
Study: 35899970

Group type: EXPERIMENTAL
Intervention: Early cardiac rehabilitation (sitting, standing, walking exercises, endurance training)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Early cardiac rehabilitation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Early cardiac rehabilitation (improvement in physical function)
Number of subjects: 87
Study: 34511330

Group type: EXPERIMENTAL
Intervention: Pre-transplant levels of circulating CLEC4C protein
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: CLEC4C alone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: CLEC4C in combination with clinical covariates from the multivariable model
Number of subjects: 219

Group type: COMPARATOR
Intervention: RADIAL score
Number of subjects: 219
Study: 36151758

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33583293

Group type: EXPERIMENTAL
Intervention: Tumour Treating Fields (TTFields) delivered via scalp; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; outcomes related to control not available.
Number of subjects: 0
Study: 32471808

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 29
Study: 35215772

Group type: EXPERIMENTAL
Intervention: Positive RT-PCR group (2292 participants)
Number of subjects: 2998

Group type: COMPARATOR
Intervention: Negative RT-PCR group (706 participants)
Number of subjects: 2998
Study: 34257646

Group type: EXPERIMENTAL
Intervention: Cavernosal sparing technique with minimal corporal dilatation after intracavernosal injection of Alprostadil
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional implantation with serial vigorous dilatations
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cavernosal sparing technique
Number of subjects: 33
Study: 36108657

Group type: EXPERIMENTAL
Intervention: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined nivolumab (240 mg IV every 2 weeks) and ipilimumab (1 mg/kg IV every 6 weeks) plus SBRT (24 Gy in three fractions at week 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ICI-naive patients receiving nivolumab and ipilimumab
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with previous ICI exposure receiving nivolumab and ipilimumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined nivolumab and ipilimumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment-related adverse events
Number of subjects: 50
Study: 33176877

Group type: EXPERIMENTAL
Intervention: Common earmuffs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Proposed molded earplugs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hearing protection devices (HPDs)
Number of subjects: 15
Study: 36213954

Group type: EXPERIMENTAL
Intervention: Wise Intervention (WI)
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Anti-stress control intervention
Number of subjects: 1085
Study: 35652136

Group type: EXPERIMENTAL
Intervention: Cuff inflation technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Magill forceps technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study: 32500740

Group type: EXPERIMENTAL
Intervention: Naked condition
Number of subjects: 51

Group type: COMPARATOR
Intervention: Clothed condition (control)
Number of subjects: 51
Study: 32990680

Group type: EXPERIMENTAL
Intervention: PDX-derived organoid (PXO) models grown under WNT-free culture conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glycome analysis of PDX and PXO models
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Secreted biomarker discovery pipeline using media supernatant of organoid cultures
Number of subjects: 10
Study: 35967525

Group type: EXPERIMENTAL
Intervention: Laparoscopic PDCI with omentectomy (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Laparoscopic PDCI without omentectomy (Group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open surgical PDCI (Group C)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Laparoscopic PDCI with omentectomy (Group A) in patients with previously failed catheter insertion
Number of subjects: 41

Group type: COMPARATOR
Intervention: Laparoscopic PDCI without omentectomy (Group B) in patients with previously failed catheter insertion
Number of subjects: 41
Study: 35500422

Group type: EXPERIMENTAL
Intervention: Isoflurane plus Epidural (IE group, n = 16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isoflurane (I group, n = 20)
Number of subjects: 36
Study: 33894554

Group type: EXPERIMENTAL
Intervention: Amplification of Positivity (AMP) treatment (n = 16)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waitlist (WL) control (n = 13)
Number of subjects: 29
Study: 35727053

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1175

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Atezolizumab (PD-L1-negative/NLR ≥4)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Atezolizumab (excluding EGFR/ALK-positive patients)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: High blood tumor mutation burden (cutoff, 16 mut/Mb)
Number of subjects: 1175
Study: 33497870

Group type: EXPERIMENTAL
Intervention: Multi-vitamin with mineral supplement (MV, n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PL, n = 11)
Number of subjects: 21
Study: 32096246

Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix (VCMX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study: 35606818

Group type: EXPERIMENTAL
Intervention: Parenting-STAIR (P‐STAIR) - 23 sessions
Number of subjects: 220

Group type: COMPARATOR
Intervention: Supportive counseling - 23 sessions
Number of subjects: 220
Study: 34671996

Group type: EXPERIMENTAL
Intervention: Namodenoson 25 mg b.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Namodenoson 12.5 mg b.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32364754

Group type: EXPERIMENTAL
Intervention: Pharmacotherapies identified through EHRs
Number of subjects: 622
Study: 36385592

Group type: EXPERIMENTAL
Intervention: Mentadent Professional® Chlorhexidine 0.05% with vitamin C (ChxC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Meridol Alito Sicuro® (SnF2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CB12® (ZnChx)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PbO)
Number of subjects: 32
Study: 33410589

Group type: EXPERIMENTAL
Intervention: Pursed-lip breathing with number counting (PLB with NC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional medical care
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comparison of PLB with NC vs Conventional medical care
Number of subjects: 110
Study: 32458450

Group type: EXPERIMENTAL
Intervention: Oro‐Pharyngeal Administration of Mother's Milk (OPAMM) - 0.2 mL prior to each gavage feeding for 24 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular gavage feeding practice
Number of subjects: 40
Study: 35526605

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg oral)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32429969

Group type: EXPERIMENTAL
Intervention: Supervised Pulmonary Hypertension Exercise Rehabilitation (SPHERe)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Best practice usual care
Number of subjects: 352
Study: 36417156

Group type: EXPERIMENTAL
Intervention: BAT2206
Number of subjects: 270

Group type: COMPARATOR
Intervention: ustekinumab (European Union)
Number of subjects: 270

Group type: COMPARATOR
Intervention: ustekinumab (USA)
Number of subjects: 270
Study: 33541836

Group type: EXPERIMENTAL
Intervention: Walnut smoothie (48 g walnuts)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo smoothie (macronutrient-matched without nuts)
Number of subjects: 10
Study: 32708600

Group type: EXPERIMENTAL
Intervention: Chair massage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 616840383

Group type: EXPERIMENTAL
Intervention: Low-He point group (puncturing at Zusanli (ST36))
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mu point group (puncturing at Zhongwan (CV12))
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: He-Mu point combination group (puncturing at ST36 and CV12)
Number of subjects: 105

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 105
Study: 35946229

Group type: EXPERIMENTAL
Intervention: Higher mobile phone usage
Number of subjects: 566
Study: 33926591

Group type: EXPERIMENTAL
Intervention: PROTECT psychotherapy (N = 25)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care (N = 15)
Number of subjects: 40
Study: 32554566

Group type: EXPERIMENTAL
Intervention: Electronic decision support tool
Number of subjects: 3904

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 3904
Study: 33630475

Group type: COMPARATOR
Intervention: Standard of care (SOC) chemotherapy and chemoradiation (N = 158)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: HAPa immunotherapy combined with SOC chemotherapy and chemoradiation (N = 145)
Number of subjects: 303
Study: 33799224

Group type: EXPERIMENTAL
Intervention: Qingfei Paidu Tang (QPT)
Number of subjects: 8939

Group type: COMPARATOR
Intervention: Not receiving QPT (Control)
Number of subjects: 8939
Study: 34424307

Group type: EXPERIMENTAL
Intervention: High-dose HBV vaccination (3 doses of 40 μg recombinant hepatitis B vaccine at 0, 1, and 2 months)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard-dose HBV vaccination (3 doses of 20 μg each at 0, 1, and 2 months)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: High-dose HBV vaccination
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard-dose HBV vaccination
Number of subjects: 107
Study: 32456514

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 1431
Study: 35416101

Group type: EXPERIMENTAL
Intervention: Prism Adaptation Training (PAT)
Number of subjects: 23
Study: 32984946

Group type: EXPERIMENTAL
Intervention: Polaprezinc (PZ) lozenge treatment started before chemotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (PZ lozenges initiated after onset of Grade 2 oral mucositis)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Polaprezinc (PZ) lozenge treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 32171499

Group type: EXPERIMENTAL
Intervention: ESP block with 20 mL of 0.5% ropivacaine bilaterally at T8 level
Number of subjects: 31

Group type: COMPARATOR
Intervention: Epidural block with 20 mL of 0.5% ropivacaine and 1 mg of morphine at T8-T9 space
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: ESP block
Number of subjects: 31
Study: 32828115

Group type: EXPERIMENTAL
Intervention: Bosentan (Tracleer®)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 32985131

Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) weight data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary trial weight data
Number of subjects: 0
Study: 36331502

Group type: EXPERIMENTAL
Intervention: Hip brace worn for at least 12 hours a day for 12 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (control group)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Hip brace intervention
Number of subjects: 66
Study: 33216012

Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 13
Study: 33435326

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula with added 2′-FL
Number of subjects: 48
Study: 33028335

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Coping planning
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Combination of three BCTs (action planning, coping planning, self-monitoring)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Combination of action planning and self-monitoring
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Action planning with coping planning
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Action planning alone
Number of subjects: 473
Study: 34475156

Group type: EXPERIMENTAL
Intervention: Amitriptyline (10-20 mg/day)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Mirtazapine (7.5-15 mg/day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 33081496

Group type: EXPERIMENTAL
Intervention: Heart failure at admission
Number of subjects: 13172
Study: 33459675

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Biofeedback postural training (BPT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Home-based exercises (Control)
Number of subjects: 90
Study: 32485422

Group type: EXPERIMENTAL
Intervention: Active Treatment A (intermittent vibrational cutaneous stimulation)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Passive Treatment B (no active stimulation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active Treatment A
Number of subjects: 32
Study: 36149628

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 158

Group type: COMPARATOR
Intervention: Combined intracervical foley’s catheter plus intravenous oxytocin infusion
Number of subjects: 158
Study: 34011413

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg tablet every other day for 2 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (identical in terms of shape, color, and smell, every other day for 2 months)
Number of subjects: 60
Study: 32764090

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic-guided dual antiplatelet therapy (DAPT) with ticagrelor for high-risk patients
Number of subjects: 250

Group type: COMPARATOR
Intervention: Clopidogrel treatment for low-risk patients
Number of subjects: 250
Study: 35765086

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with cryotherapy (TC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Topical anesthesia alone (T)
Number of subjects: 80
Study: 33721611

Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg/day
Number of subjects: 346

Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 346
Study: 35296791

Group type: EXPERIMENTAL
Intervention: Preconception lifestyle intervention
Number of subjects: 315
Study: 32616069

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in RA-BUILD
Number of subjects: 0
Study: 33835187

Group type: EXPERIMENTAL
Intervention: Pararectus approach
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 8
Study: 33618120

Group type: EXPERIMENTAL
Intervention: Physical activity intervention over 16 weeks
Number of subjects: 15
Study: 33038969

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36608972

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy plus a Memory Support Intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cognitive Therapy-as-usual
Number of subjects: 178
Study: 34078971

Group type: EXPERIMENTAL
Intervention: Nutritional intervention during allo‐HSCT
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 47
Study: 32935866

Group type: EXPERIMENTAL
Intervention: MR 200 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MR 400 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 36325947

Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33351540

Group type: EXPERIMENTAL
Intervention: Hybrid-CR (telehealth sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (S-CR)
Number of subjects: 47
Study: 32928659

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice daily
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368
Study: 34451976

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine combined with annual influenza vaccine
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study: 32969518

Group type: EXPERIMENTAL
Intervention: Confirm Rx
Number of subjects: 142

Group type: COMPARATOR
Intervention: Reveal LINQ
Number of subjects: 142
Study: 36438071

Group type: EXPERIMENTAL
Intervention: Silymarin (140 mg every 8 hours for 4 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (same tablet shape, same dosage as silymarin)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 56
Study: 33435878

Group type: EXPERIMENTAL
Intervention: Volunteer-supported outdoor walking intervention (30-50 minutes, three times a week for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (two lectures covering health-related topics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volunteer-supported outdoor walking intervention
Number of subjects: 0